Vaccinations have been completed and Valneva expects VALOR trial outcomes to be announced in the first half of 2026, followed by regulatory submissions as planned. Pfizer aims to submit a Biologics ...

Pfizer (PFE) has reportedly decided to sell its entire remaining stake in BioNTech (BNTX), showing a lack of confidence in ...

The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

A wave of lawsuits with novel strategies show that the search for Covid vengeance — and jury awards — has gained force under ...

The German biopharmaceutical company BioNTech finds itself at a critical juncture following a significant divestment by its ...

Anonymized data shared with pharma will remain hidden from public after two-year legal battle, based on hidden evidence of "triangulating" the deceased's identities and assumption their relatives ...

Pfizer sell 508M stake in BioNTech through an overnight block trade, marking its exit from the COVID-19 vaccine partner's equity.

A BioNTech spokesperson downplayed the news, insisting that the two companies remain “close” and have a “strong collaboration ...

Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March ...

--Pfizer is trying to sell its stake in BioNTech SE, Bloomberg reported, citing people familiar with the matter. --Pfizer is offering 4.55 million American depositary receipts for $108 to $111.70 a ...

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Dave Denton, Chief Financial Officer, Executive Vice President, at the Jefferies ...